Blog
RSS FeedPosted by Michael Wonder on 21 Dec 2020
Closure of the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis
21 December 2020 - A plain language summary for the post-market review of the use of biologics in the treatment ...
Posted by Michael Wonder on 20 Dec 2020
Lung cancer drug subsidy will make 'big difference' for patients
20 December 2020 - If you’re a non-smoking woman and you develop a cough, the last thing you think you've ...
Posted by Michael Wonder on 19 Dec 2020
Karyopharm announces FDA approval of Xpovio (selinexor) as a treatment for patients with multiple myeloma after at least one prior therapy
18 December 2020 - Oral Xpovio now available as a treatment option for patients with multiple myeloma as early as first ...
Posted by Michael Wonder on 18 Dec 2020
FDA approves first adjuvant therapy for most common type of lung cancer
18 December 2020 - Today, the U.S. FDA approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell ...
Posted by Michael Wonder on 18 Dec 2020
Medicines for hepatitis C remain in the high-cost protection after TLV's reconsideration
18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis ...
Posted by Michael Wonder on 18 Dec 2020
FDA approves first oral hormone therapy for treating advanced prostate cancer
18 December 2020 - Today, the U.S. FDA approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. ...
Posted by Michael Wonder on 18 Dec 2020
Novaremed receives fast track designation from the FDA for NRD135S.E1 for the treatment of painful diabetic peripheral neuropathy
18 December 2020 - Novaremed announced today that it has received fast track designation from the U.S. FDA for the development ...
Posted by Michael Wonder on 18 Dec 2020
Novo Nordisk files for EU regulatory approval of once weekly semaglutide 2.4 mg for weight management
18 December 2020 - Novo Nordisk today announced the submission of a marketing authorisation application to the EMA for subcutaneous semaglutide ...
Posted by Michael Wonder on 18 Dec 2020
Blueprint Medicines submits supplemental new drug application to FDA for Ayvakit (avapritinib) for the treatment of advanced systemic mastocytosis
17 December 2020 - Blueprint Medicines today announced the submission of a supplemental new drug application to the U.S. Food FDA ...
Posted by Michael Wonder on 18 Dec 2020
Recommendations made by the PBAC - November 2020
18 December 2020 - The recommendations from the November 2020 PBAC meeting are now available. ...
Posted by Michael Wonder on 18 Dec 2020
Report on the collection of under co-payment data 2019-20
18 December 2020 - The report on the collection of under co-payment data 2019-20 is now available. ...
Posted by Michael Wonder on 18 Dec 2020
Sandoz Canada receives authorisation from Health Canada to launch new biosimilar Hyrimoz (adalimumab)
17 December 2020 - Hyrimoz approved for use in all same indications as reference medicine* including rheumatology, gastro-enterology and dermatology. ...
Posted by Michael Wonder on 17 Dec 2020
FDA approves Amgen's Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab)
17 December 2020 - Fifth FDA Approval From Amgen's Biosimilars Portfolio. ...
Posted by Michael Wonder on 17 Dec 2020
Novartis investigational oral therapy iptacopan (LNP023) receives FDA breakthrough therapy designation for PNH and rare paediatric disease designation for C3G
16 December 2020 - Iptacopan is in development for paroxysmal nocturnal haemoglobinuria, as well as C3 glomerulopathy and several other ...
Posted by Michael Wonder on 17 Dec 2020
Decibel Therapeutics announces DB-020 has been granted fast track designation by the U.S. FDA
17 December 2020 - Decibel Therapeutics today announced that their clinical product candidate, DB-020, has been granted fast track designation ...